In this article, we will discuss the 5 Cheap Penny Stocks to Invest In Now. For deeper discussion and analysis, read 12 Cheap Penny Stocks to Invest In Now.

5. AlTi Global, Inc. (NASDAQ:ALTI)

On March 31, AlTi Global, Inc. (NASDAQ:ALTI) reported fourth-quarter EPS of $(0.20), a notable improvement from $(0.55) in the prior-year period, alongside revenue of $88.3 million compared to $51.5 million last year. The significant year-over-year revenue expansion, coupled with a marked narrowing of losses, underscores strengthening operating momentum and suggests that the firm is beginning to realize scale benefits following its recent strategic combination, reinforcing the potential for continued earnings normalization and value creation.

On the same day, AlTi Global, Inc. (NASDAQ:ALTI) announced the appointment of Nancy Curtin as Interim Chief Executive Officer and a member of its Board of Directors, effective immediately. Curtin, who has served as Global Chief Investment Officer since the firm’s formation, succeeds Michael Tiedemann, who will remain in an advisory role to support a smooth leadership transition. The appointment of an experienced internal executive with deep investment expertise provides continuity in strategic direction and reinforces confidence in the firm’s ability to execute on its long-term growth initiatives.

AlTi Global, Inc. (NASDAQ:ALTI) is a leading independent global wealth and asset manager formed in January 2023 through the combination of Tiedemann Wealth Management, Alvarium Investments, and Cartesian Growth Corporation. Headquartered in New York, the firm serves ultra-high-net-worth individuals, families, and institutions through a comprehensive platform spanning wealth management, alternative investments, and fiduciary services. With improving financial performance, leadership stability, and increasing scale, AlTi is well-positioned to capitalize on growing demand for sophisticated wealth solutions, supporting a compelling investment case with meaningful upside potential.

4. SBC Medical Group Holdings Incorporated (NYSE:SBC)

On March 27, SBC Medical Group Holdings Incorporated (NYSE:SBC) reported fourth-quarter revenue of $40 million, below the consensus estimate of $45.44 million. Management attributed the year-over-year revenue decline to deliberate structural changes, including a 2024 business restructuring and revisions to franchise fee arrangements implemented in April 2025. While these initiatives weighed on near-term financial performance, they represent strategic actions aimed at enhancing long-term operational sustainability, with the majority of their financial impact now largely absorbed.

Earlier, on March 6, BTIG analyst Sam Eiber initiated coverage on SBC Medical Group Holdings Incorporated (NYSE:SBC) with a Buy rating and an $8 price target, highlighting the company’s position as the leading aesthetic medical group in Japan, with more than 250 franchises and over 6.5 million annual patient visits. The analyst emphasized that the company offers exposure to a non-U.S. growth story with multiple expansion opportunities, while currently trading at a valuation discount relative to its global peers, presenting an attractive entry point for investors.

SBC Medical Group Holdings Incorporated (NYSE:SBC) is a Medical Services Organization (MSO) and holding company for Japan’s Shonan Beauty Clinic network, providing consulting, marketing, and operational support services across more than 200 clinics. Headquartered in Irvine, California, the company operates at the intersection of healthcare and consumer aesthetics, a segment benefiting from strong secular demand trends. As restructuring efforts conclude and growth initiatives gain traction, SBC appears well-positioned to drive improved financial performance, supporting a favorable risk-reward profile and significant upside potential.

3. OPAL Fuels Inc. (NASDAQ:OPAL)

On March 27, B. Riley lowered its price target on OPAL Fuels Inc. (NASDAQ:OPAL) to $4 from $5 while maintaining a Buy rating, reflecting updated assumptions following recent refinancing activities and anticipated funding requirements to support capital expenditures through 2027. The revised outlook incorporates near-term financial adjustments while maintaining a constructive long-term view on the company’s growth trajectory. Previously, on March 17, Goldman Sachs raised its price target modestly to $2.40 from $2.10 while maintaining a Sell rating, indicating a more cautious stance despite incremental valuation adjustments.

On March 9, 2026, OPAL Fuels Inc. (NASDAQ:OPAL) announced the closing of a $180 million preferred equity facility with an affiliate of its majority shareholder, Fortistar, including an initial $120 million draw and an additional $60 million available for future funding. A substantial portion of the proceeds was used to redeem existing preferred units, with the remainder allocated toward general corporate purposes, including capital expenditures and project financing. Management indicated that the financing strengthens the company’s ability to execute on its next phase of growth, particularly in expanding renewable natural gas (RNG) production capacity and fueling infrastructure. While the preferred units carry a 12% annual distribution, the capital infusion enhances liquidity and supports long-term project development.

OPAL Fuels Inc. (NASDAQ:OPAL) is a leading producer and distributor of renewable natural gas, focused on serving heavy-duty transportation markets while also developing and operating RNG production and fueling infrastructure across the United States. Positioned at the forefront of the energy transition, the company stands to benefit from increasing regulatory support and demand for low-carbon fuel alternatives. With improved access to capital and a clear pathway to scaling its asset base, OPAL presents a compelling opportunity for investors seeking exposure to high-growth clean energy infrastructure with significant long-term upside.

2. Niagen Bioscience, Inc. (NASDAQ:NAGE)

On March 31, Niagen Bioscience, Inc. (NASDAQ:NAGE) announced a strategic partnership with OneSpaWorld to offer pharmaceutical-grade Niagen IV treatments across more than 80 medi-spa clinics onboard premium cruise ships. This marks the company’s first entry into the cruise ship channel, expanding its Niagen Plus provider network and opening a new high-margin distribution avenue. The collaboration strengthens Niagen’s global footprint and aligns with its strategy to scale its injectable offerings beyond traditional U.S.-based clinical settings.

Previously, on March 19, the company’s board authorized an expansion of its share repurchase program, increasing the total authorization from $10 million to $20 million, signaling confidence in its intrinsic value and long-term growth prospects. Additionally, on March 5, Canaccord maintained a Buy rating on Niagen Bioscience, Inc. (NASDAQ:NAGE) while lowering its price target to $13 from $14 following fourth-quarter results, noting continued strong demand in the core business and highlighting incremental upside potential from the company’s growing injectable segment.

Niagen Bioscience, Inc. (NASDAQ:NAGE), formerly known as ChromaDex Corp., is a biotechnology company focused on healthy aging and NAD+ research, with flagship products including Niagen (nicotinamide riboside) and Tru Niagen. Headquartered in Los Angeles, the company operates at the intersection of consumer health and advanced bioscience. With expanding distribution channels, shareholder-friendly capital allocation, and strong demand fundamentals, Niagen is well-positioned to capitalize on the growing longevity market, supporting a high-upside investment thesis driven by both core and emerging revenue streams.

1. Rimini Street, Inc. (NASDAQ:RMNI)

On April 1, Rimini Street, Inc. (NASDAQ:RMNI) announced a series of first-quarter debt reduction initiatives alongside an amendment to its existing credit agreement. The company reduced its outstanding term loan by $10.9 million during the quarter, bringing the balance down to $58.4 million as of March 31, 2026. In addition, the amended agreement increases the annual limit for common stock repurchases to $20 million beginning in fiscal 2026, with a total of $50 million permitted through April 2029. With $36.7 million still available under the existing authorization, these developments reflect a strengthened balance sheet and enhanced capital return flexibility, signaling management’s confidence in the company’s financial position and long-term cash flow generation.

A day earlier, Rimini Street, Inc. (NASDAQ:RMNI) announced that Lotte Rental, South Korea’s leading car rental provider, has selected the company to deliver support for its Oracle and SAP systems. This customer win highlights Rimini Street’s continued traction in securing large, enterprise clients and reinforces the value proposition of its third-party support model, which enables organizations to optimize IT spending while maintaining mission-critical software systems.

Rimini Street, Inc. (NASDAQ:RMNI) is a global provider of third-party enterprise software support services, catering to users of Oracle, SAP, and other major enterprise platforms. Headquartered in Las Vegas and founded in 2005, the company focuses on helping clients reduce IT operating costs while extending the useful life of their existing software investments. With ongoing debt reduction, expanded shareholder return capacity, and continued client acquisition momentum, Rimini Street is well-positioned to drive sustainable earnings growth, supporting a compelling investment case with meaningful upside potential.

READ NEXT: 13 Best Strong Buy AI Stocks to Invest In Now and Lithium Stocks List: 9 Biggest Lithium Stocks.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.